Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Cancer Type/Condition:
Ovarian epithelial cancer
Trial Type:
Treatment
Treatment/Intervention:
antiangiogenesis therapy
Trial Status:
Active
Trial Phase:
Phase III
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
GOG-0212
, NCT00108745
2.
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AVF4095g
, NCT00434642
3.
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
MREC-ICON7
, EUDRACT-2005-003929-22, ISRCTN91273375, ROCHE-MREC-ICON7, EU-20730, ICON7, MREC-06/MRE02/52, NCT00483782
4.
Carboplatin and Paclitaxel With or Without Cediranib in Treating Women With Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
MRC-NCRI-ICON6
, MRC-NCRI-ICON6, EUDRACT-2007-001346-41, EU-20765, ZENECA-MRC-NCRI-ICON6, NCT00544973
5.
Pazopanib in Treating Patients With Metastatic Soft Tissue Sarcoma That Has Relapsed or Not Responded to Treatment
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
EORTC-62072
, EORTC 62072, EU-20887, NCT00753688, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
6.
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
110655
, AGO-OVAR16, NCT00866697
7.
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-0252
, GOG -0252, NCT00951496
Select All on Page
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
